Characterization of germline copy number variation in high-risk African American families with prostate cancer - Abstract

BACKGROUND: Prostate cancer is a complex multi-allelic disease and the most common malignancy in men.

The incidence of prostate cancer in African American men is more than twice as high as that of any other race. Despite the high prevalence of prostate cancer amongst African American men, this population has been under represented in genetic studies of prostate cancer. Although genomic copy number variations (CNVs) have been detected in prostate tumors, this is the first study describing germline CNVs in African American hereditary prostate cancer families.

METHODS: Ten high-risk African American families with three or more affected individuals and with an early age of onset were recruited. From these families, 37 individuals, including 23 affected males, and 14 unaffected males, were selected for CNV analysis. Array comparative genomic hybridization was used to characterize germline CNVs unique to African American men with hereditary prostate cancer.

RESULTS: Through common aberration analysis in affected family members; novel CNVs were identified at chromosomes 1p36.13 and 16q23.3. Differential analysis comparing affected and unaffected family members identified 9.4 kb duplication on chromosome 14q32.33 which segregate with prostate cancer patients in these high-risk families.

CONCLUSIONS: The duplication at 14q32.33 encompasses IGHG3 gene which has been shown to have both significant gains in copy number as well as overexpression in prostate tumors in African Americans. These CNVs may represent a component of genetic predisposition which contributes to the high prevalence and mortality of prostate cancer in African American men.

Written by:
Ledet EM, Hu X, Sartor O, Rayford W, Li M, Mandal D.   Are you the author?
Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, Louisiana.

Reference: Prostate. 2012 Oct 11. Epub ahead of print.
doi: 10.1002/pros.22602


PubMed Abstract
PMID: 23060098

UroToday.com Prostate Cancer Section